Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

24/7 Wall St. aims to present some farther-looking insights based on Novo Nordisk’s own numbers ... the UK’s Association of British Pharmacy Industry over ethics violations tantamount to ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

an online weight loss company called Noom has begun selling smaller doses of compounded versions of Novo Nordisk's Wegovy GLP-1 drug. This development comes as the compounding pharmacy industry ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will resign from the company after a short transition period. His replacement has not yet been found. Novo Nordisk stock is down 50% in 12 months ...

Novo Nordisk — the Danish drug manufacturer that makes Wegovy — today announced that Lars Fruergaard Jørgensen, its CEO, is stepping down from the CEO post. The company announced that it made ...

Novo Nordisk A/S is replacing Chief Executive Officer ... for its Wegovy obesity shots that transformed the weight-loss industry and made the Danish company the star of corporate Europe.